Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Sentryx Bv |
| Country | Netherlands |
| Start Date | Apr 01, 2023 |
| End Date | Mar 31, 2026 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190122961 |
There is a troubling lack of effective pain treatments after major surgery. Especially after musculoskeletal procedures, patients experience debilitating pain now treated with opioids. Opioids provide insufficient pain relief, have many toxic side-effects, and are highly addictive.
Pain and opioid-related side-effects impede early mobilisation and recovery and are the primary reasons for extended hospital stays.SentryX is developing revolutionary drug delivery technology to extend the effects of a well-established local pain blocker called bupivacaine.
Its initial use case in spine fixation surgery, Bupi-Ring, delivers bupivacaine directly to the surgical site for more than 72 hours without changing the existing surgical workflow.
Non-opioid local pain relief in this critical early phase of recovery will promote early mobilisation, shorten hospital stays, prevent complications, and save costs. This project will demonstrate Bupi-Rings safety and efficacy in humans for the first time.
Sentryx Bv
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant